Aradigm Corporation Profile last edited on: 11/2/2023
CAGE: 3BEF7
UEI: NSTHG7YU2KU7
Business Identifier: Inhalation therpay for treatment of severe respiratory disease. 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 15
County: Alameda
Congr. District: 15
County: Alameda
Public Profile
Aradigm Corporation (OTC PINK: ARDM) is a specialty pharmaceutical company focused on development and commercialization of products for the treatment and prevention of severe respiratory diseases. having gone public before they became SBIRInvolved, the firm's lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq and Lipoquin that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis, cystic fibrosis, and non-tuberculosis mycobacterium. The company is also developing inhaled ciprofloxacin formulations for treatment of patients with cystic fibrosis, and has tested for the prevention and treatment of inhaled bioterrorism infections, such as oxiella burnetii or Q fever, inhalation anthrax, tularemia, melioidosis and pneumonic plague.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
25-49Revenue Range
2.5M-5MVC funded?
YesPublic/Private
Publicly TradedStock Info
OTC : ARDMIP Holdings
150-249Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2018 | 2 | NIH | $972,650 | |
| Project Title: In Vitro and in Vivo Efficacy of Liposomal Ciprofloxacin Formulations Against Mycobacterium Avium and Mycobacterium Abscessus | ||||
| 2013 | 1 | NIH | $339,824 | |
| Project Title: Development and Validation of Test for Gastro-Esophageal Reflux with Aspiration | ||||
| 2013 | 1 | NIH | $277,768 | |
| Project Title: In Vitro And In Vivo Efficacy Of Liposomal Ciprofloxacin Formulations Against Myc | ||||
| 2005 | 1 | NIH | $153,151 | |
| Project Title: Pulmonary delivery of nicotine using the AERx System | ||||
| 2003 | 1 | Army | $70,000 | |
| Project Title: Developing Human-Compatible Needleless Delivery Systems for Administering Bioscavengers | ||||
Key People / Management
Igor Gonda -- President & Chief Executive Officer
James D Blanchard
Deepa Deshpande
Juergen Froehlic -- Chief Medical Officer
Nancy Pecota -- Chief Financial Officer
James D Blanchard
Deepa Deshpande
Juergen Froehlic -- Chief Medical Officer
Nancy Pecota -- Chief Financial Officer
